Synergistic Anti-CD25 Antibody-Maytansine Conjugates with Integrated Technologies
Legal Citation
Summary of the Inventive Concept
The invention integrates anti-CD25 antibody-maytansine conjugates with cutting-edge technologies like blockchain, AI, IoT, and graphene materials to create a new generation of targeted cancer therapeutics with enhanced efficacy, safety, and patient-centric care.
Background and Problem Solved
The original patent disclosed anti-CD25 antibody-maytansine conjugates with promising therapeutic potential. However, these conjugates lacked advanced features for tracking, personalized medicine, and optimized delivery. The new inventive concept addresses these limitations by combining the conjugates with synergistic technologies to create a more powerful and efficient system.
Detailed Description of the Inventive Concept
The inventive concept comprises a conjugate of formula (I) integrated with a blockchain-based tracking module for secure and transparent monitoring of the conjugate's distribution and administration. Additionally, the conjugate is used in combination with AI-assisted personalized medicine to predict optimal dosing and treatment regimens based on patient-specific data. Furthermore, the conjugate is formulated with a nanoparticle-based delivery system featuring IoT-enabled sensors for real-time monitoring of in vivo drug delivery. The conjugate may also include a graphene-based material for enhanced stability and bioavailability, functionalized with a targeting moiety for specific delivery to cancer cells. Finally, the conjugate can be manufactured using a 3D printing-based process integrated with AI-assisted design and simulation tools for optimized conjugate synthesis and characterization.
Novelty and Inventive Step
The new claims introduce novel combinations of the anti-CD25 antibody-maytansine conjugates with distinct technologies, providing a synergistic effect that enhances the conjugates' therapeutic potential. The inventive concept's novelty lies in the integration of these technologies to create a more powerful and efficient system, which is non-obvious compared to the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different blockchain platforms, AI algorithms, or IoT sensors. Variations may involve the integration of other emerging technologies, such as quantum computing or synthetic biology, to further enhance the conjugates' performance.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the development of targeted cancer therapeutics. The integrated technologies can improve patient outcomes, reduce healthcare costs, and enhance the overall efficiency of cancer treatment. The market for such therapeutics is substantial, with an estimated global value of over $100 billion by 2025.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/6807 |
| C | C07 | C07K16/2866 |
| A | A61 | A61K47/65 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Protein-small molecule therapeutic conjugates, specifically antibody-drug conjugates (ADCs) targeting CD25 for cancer therapeutics, requiring advanced knowledge in molecular biology, protein engineering, drug delivery systems, and nanotechnology
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with a PhD in biomedical engineering, molecular biology, or pharmaceutical sciences, having expertise in antibody conjugation techniques, drug delivery technologies, and interdisciplinary medical innovation
Obviousness Rationale
A PHOSITA would recognize that integrating emerging technologies like blockchain, AI, and IoT with existing antibody-maytansine conjugate platforms represents a predictable extension of known drug development strategies. The technical combinations disclosed leverage standard engineering principles of modular design and technology integration. The variations demonstrate incremental improvements using well-established technological approaches that would be apparent to a skilled researcher in the field of targeted therapeutics.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,637 |
|---|---|
| Title | Anti-CD25 antibody-maytansine conjugates and methods of use thereof |
| Assignee(s) | R.P. Scherer Technologies, LLC |